Regional Biocontainment Laboratory (RBL) for Region V
Project Number1UC6AI058606-01
Former Number1C06AI058606-01
Contact PI/Project LeaderMOFFAT, JOHN KEITH
Awardee OrganizationUNIVERSITY OF CHICAGO
Description
Abstract Text
DESCRIPTION (provided by applicant): The Ricketts (Regional Biocontainment) Laboratory would be constructed in a secure area leased from the Department of Energy at Argonne National Laboratory near Chicago, Illinois. It would serve the research, translational research, research training, service, and emergency response functions of the Midwest RCE (Regional Center of Excellence). The Midwestern RCE includes Region V scientists from Argonne National Laboratory, Battelle Memorial Institute, Illinois Institute of Technology, Mayo Clinic, Medical College of Wisconsin, Michigan State University, Northwestern University, Notre Dame University, Purdue University, University of Chicago, University of Illinois at Urbana-Champaign, University of Michigan, and University of Wisconsin. Intellectual contributions from over 100 scientists produced twenty-five inter-disciplinary, inter-institutional research programs selected by competitive peer review. The programs focus on studying CDC Category A Select Agents to develop new therapeutics, vaccines and diagnostic devices. Review mechanisms will provide access for NIAID supported non-RCE scientists, including proprietary research. An emergency response plan provides training and, when necessary complete commitment to emergency responders. The Ricketts Laboratory would have 54,100 square feet (27,500 net square feet (NSF)), with 8,900 NSF of BSL-2/BSL-3 molecular laboratory space and 13,300 NSF of BSL-2/BSL-3 animal research laboratories. It would have the capacity for simultaneous study of four or more different Select Agent Category A pathogens, by the research groups of five principal investigators and thirty-five staff scientists, with a total holding capacity for about 30,000 mice or other experimental animals.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
005421136
UEI
ZUE9HKT2CLC9
Project Start Date
30-September-2003
Project End Date
30-June-2008
Budget Start Date
30-September-2003
Budget End Date
30-June-2008
Project Funding Information for 2003
Total Funding
$17,374,817
Direct Costs
$17,374,817
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2003
National Institute of Allergy and Infectious Diseases
$17,374,817
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1UC6AI058606-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1UC6AI058606-01
Patents
No Patents information available for 1UC6AI058606-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1UC6AI058606-01
Clinical Studies
No Clinical Studies information available for 1UC6AI058606-01
News and More
Related News Releases
No news release information available for 1UC6AI058606-01
History
No Historical information available for 1UC6AI058606-01
Similar Projects
No Similar Projects information available for 1UC6AI058606-01